知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

116 条记录 (耗时 0.024 秒)

    Intracorporeal medicaments for photodynamic treatment of disease
    2.
    发明申请
    Intracorporeal medicaments for photodynamic treatment of disease 审中-公开
    用于光动力治疗疾病的体内药物

    公开(公告)号：US20070010575A1

    公开(公告)日：2007-01-11

    申请号：US11522145

    申请日：2006-09-15

    申请人： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

    发明人： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

    IPC分类号： A61K31/353

    CPC分类号： A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

    摘要： New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

    摘要翻译： 描述了新的体内光动力学药物和用于治疗人或动物组织中的这种光动力药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物以包括液体，半固体，固体或气溶胶递送载体的各种制剂生产。

    Treatment of in-stent restenosis using cytotoxic radiation
    6.
    发明授权
    Treatment of in-stent restenosis using cytotoxic radiation 失效
    使用细胞毒性辐射治疗支架内再狭窄

    公开(公告)号：US06520957B1

    公开(公告)日：2003-02-18

    申请号：US09712709

    申请日：2000-11-14

    申请人： Michael Kasinkas ,  Robert A. Van Tassel

    发明人： Michael Kasinkas ,  Robert A. Van Tassel

    IPC分类号： A61B1818

    CPC分类号： A61N5/0601 ,  A61B17/22 ,  A61B18/24 ,  A61B2017/22002 ,  A61B2017/22059 ,  A61B2017/22064 ,  A61B2017/22087 ,  A61B2018/2261 ,  A61N2005/0661

    摘要： Methods and systems are disclosed for treating in-stent restenosis using radiation having a wavelength sufficient to kill or promote cellular death (e.g., through programmed cell death), or otherwise remove smooth muscle cells which have proliferated, or which might otherwise proliferate, in the proximity of (i.e., within, around or adjacent to) a stent within a body lumen, causing (or potentially causing) at least partial blockage of the lumen. Devices are disclosed for providing such therapeutic radiation at the stent with or without concurrent mechanical (e.g. balloon dilation) angioplasty. Treatment methods are also disclosed which include irradiating smooth muscle cells in the region of the stenosis with non-ablative, cytotoxic radiation, such as UV radiation. A cytotoxic, photoactivatable chromophore may also be delivered to the treatment site prior to irradiation. The methods and systems can be used prophylactically or to treat in-stent restenosis after blockage has occurred without further damage to surrounding tissue.

    摘要翻译： 公开了用于使用具有足以杀死或促进细胞死亡（例如通过程序性细胞死亡）的波长的辐射治疗支架内再狭窄的方法和系统，或以其它方式去除已经增殖或可能在其中增殖的平滑肌细胞 支架在体腔内（即，在其内，周围或邻近）附近，引起（或潜在地引起）至少部分阻塞内腔。 公开了用于在具有或不具有并行机械（例如球囊扩张）血管成形术的情况下在支架处提供这种治疗放射线的装置。 还公开了治疗方法，其包括在非消融性，细胞毒性辐射（例如UV辐射）下在狭窄区域照射平滑肌细胞。 在照射之前，细胞毒性的可光活化的发色团也可以被递送到治疗部位。 该方法和系统可以预防性地使用或在阻塞发生后治疗支架内再狭窄，而没有对周围组织的进一步损伤。

    Medicaments for chemotherapeutic treatment of disease
    7.
    发明申请
    Medicaments for chemotherapeutic treatment of disease 失效
    化疗药物治疗疾病

    公开(公告)号：US20020161035A1

    公开(公告)日：2002-10-31

    申请号：US09900355

    申请日：2001-07-06

    申请人： Photogen, Inc.

    发明人： H. Craig Dees ,  Timothy C. Scott

    IPC分类号： A61K039/395 ,  A61K031/352

    CPC分类号： A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

    摘要： New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

    摘要翻译： 描述了新的化学治疗药物和用于治疗人或动物组织中的这种化学治疗药物的某些医疗用途和方法，其中这种药物的主要活性成分是卤化呫吨或卤代呫吨衍生物。 优选地，卤代呫吨是玫瑰红或玫瑰红的功能衍生物。 卤代呫吨构成一系列有用的化学治疗剂，其在某些组织中提供选择性的，持续的积累。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物可用于体内或局部给药的各种制剂，包括在液体，半固体，固体或气溶胶输送载体中。

    Solid state source for generating intense light for photomedicine
    8.
    发明授权
    Solid state source for generating intense light for photomedicine 失效
    用于产生强光的光固化光源

    公开(公告)号：US06254596B1

    公开(公告)日：2001-07-03

    申请号：US09103453

    申请日：1998-06-24

    申请人： Nabil M. Lawandy

    发明人： Nabil M. Lawandy

    IPC分类号： A61B1818

    CPC分类号： A61N5/062 ,  A61B18/20 ,  A61B2017/22087 ,  A61N5/0601 ,  A61N2005/067

    摘要： This invention teaches an optical source (10) for performing photomedicine. The optical source includes a Nd:YLF laser (12) having an output providing light having a wavelength of 1.053 micrometers; a frequency doubler (13) that is optically coupled to the laser output for converting a portion of the light to frequency doubled light, the frequency doubler having an output providing frequency doubled light having a wavelength of 526.5 nm; coupled to the output of the frequency doubler, a unit (14) for shifting the frequency doubled light to light having a longer wavelength of about 630 nm; and means (16) for conveying the light having the longer wavelength to the region of tissue. In one embodiment of this invention the shifting unit includes a device for performing stimulated Raman scattering of the frequency doubled light. The invention teaches the optical source and methods for using the optical source for performing photomedicine, such as, for treating a region of tissue to remove port wine stains, to remove a tattoo, and to remove one or more hair follicles, disposed therein.

    摘要翻译： 本发明教导了用于进行光电疗法的光源（10）。 光源包括具有提供波长为1.053微米的光的输出的Nd：YLF激光器（12）; 与激光输出光学耦合的倍频器（13），用于将一部分光转换成倍频光，所述倍频器具有提供波长为526.5nm的倍频光; 耦合到倍频器的输出，用于将倍频光移动到具有约630nm的较长波长的光的单元（14）; 以及用于将具有较长波长的光传送到组织区域的装置（16）。 在本发明的一个实施例中，移位单元包括用于执行倍频光的受激拉曼散射的装置。 本发明教导了用于执行光学医学的光源的光源和方法，例如用于处理组织区域以除去葡萄酒葡萄酒污渍，去除纹身，以及去除设置在其中的一个或多个毛囊。